Ligands at the free fatty acid receptors 2/3 (GPR43/GPR41)

Handbook of Experimental Pharmacology

Volumn 236, Issue , 2017, Pages 17-32

  Milligan, Graeme ^a   Bolognini, Daniele ^a   Sergeev, Eugenia ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Diabetes; Free fatty acids; Inflammation; Microbiota

Indexed keywords

3 (CYCLOPENTYLMETHYL) 4 [CYCLOPROPYL [4 (2,6 DICHLOROPHENYL)THIAZOL 2 YL]AMINO] 4 OXOBUTANOIC ACID; 3 BENZYL 4 [CYCLOPROPYL [4 (2,5 DICHLOROPHENYL)THIAZOL 2 YL]AMINO] 4 OXOBUTANOIC ACID; 3 [2 (3 CHLOROPHENYL)ACETAMIDO] 4 [4 (TRIFLUOROMETHYL)PHENYL]BUTANOIC ACID; 4 (FURAN 2 YL) 2 METHYL 5 OXO N (2 TOLYL) 1,4,5,6,7,8 HEXAHYDROQUINOLINE 3 CARBOXAMIDE; 4 [4 (DIMETHYLAMINO)PHENYL] N (3,5 DIMETHYLPHENYL) 6 METHYL 2 OXO 1,2,3,4 TETRAHYDRO 5 PYRIMIDINECARBOXAMIDE; 4 [4 (DIMETHYLAMINO)PHENYL] N (4,5 DIMETHYLPHENYL) 6 METHYL 2 OXO 1,2,3,4 TETRAHYDRO 5 PYRIMIDINECARBOXAMIDE; 4 [[1 (BENZO[B]THIOPHENE 3 CARBONYL) 2 METHYLAZETIDINE 2 CARBONYL](3 CHLOROBENZYL)AMINO]BUTYRIC ACID; 5 (2 CHLOROPHENYL) 1 [2' METHOXY(1,1' BIPHENYL) 4 CARBONYL]PYRROLIDINE 2 CARBOXYLIC ACID; AR 420626; AZ 1729; CARBOXYLIC ACID DERIVATIVE; CMP 71; CYTOKINE RECEPTOR AGONIST; CYTOKINE RECEPTOR ANTAGONIST; FR 900359; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 41; G PROTEIN COUPLED RECEPTOR 43; MECMP 71; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; FFAR3 PROTEIN, HUMAN; G-PROTEIN COUPLED RECEPTOR 43, HUMAN; LIGAND;

BINDING AFFINITY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; OBESITY; STRUCTURE ACTIVITY RELATION; AGONISTS; ALLOSTERISM; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; PHYSIOLOGY;

ALLOSTERIC REGULATION; ANIMALS; HUMANS; LIGANDS; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED;

EID: 85014070872     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/164_2016_49     Document Type: Chapter

References (55)

1. Agus A, Denizot J, Thévenot J, Martinez-Medina M, Massier S, Sauvanet P, Bernalier-Donadille A, Denis S, Hofman P, Bonnet R, Billard E, Barnich N (2016) Western diet induces a shift in microbiota composition enhancing susceptibility to adherent-invasive E. coli infection and intestinal inflammation. Sci Rep 6:19032
2. Ang Z, Ding JL (2016) GPR41 and GPR43 in obesity and inflammation - protective or causative? Front Immunol 7:28
3. Ballesteros JA, Weinstein H (1995) Integrated methods for modeling G-protein coupled receptors. Methods Neurosci 25:366-428
4. Bolognini D, Tobin AB, Milligan G, Moss CE (2016a) The pharmacology and function of short chain fatty acid receptors. Mol Pharmacol 89:388-398
5. Bolognini D, Moss CE, Nilsson K, Petersson AU, Donnelly I, Sergeev E, Konig GM, Kostenis E, Kurowska-Stolarska M, Miller A, Dekker N, Tobin AB, Milligan G (2016b) A novel allosteric activator of free fatty acid 2 receptor displays unique Gi-functional bias. J Biol Chem 291:18915-18931
6. Brantis C, Ooms F, Bernard J (2011) Novel amino acid derivatives and their use as gpr43 receptor modulators. PCT Int Appl WO2011092284
7. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, Muir AI, Wigglesworth MJ, Kinghorn I, Fraser NJ, Pike NB, Strum JC, Steplewski KM, Murdock PR, Holder JC, Marshall FH, Szekeres PG, Wilson S, Ignar DM, Foord SM, Wise A, Dowell SJ (2003) The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 278:11312-11319
8. Brown AJ, Tsoulou C, Ward E, Gower E, Bhudia N, Chowdhury F, Dean TW, Faucher N, Gangar A, Dowell SJ (2015) Pharmacological properties of acid N-thiazolylamide FFA2 agonists. Pharmacol Res Perspect 3, e00141
9. Engelstoft MS, Park WM, Sakata I, Kristensen LV, Husted AS, Osborne-Lawrence S, Piper PK, Walker AK, Pedersen MH, Nohr MK, Pan J, Sinz CJ, Carrington PE, Akiyama TE, Jones RM, Tang C, Ahmed K, Offermanns S, Egerod KL, Zigman JM, Schwartz TW (2013) Seven transmembrane G protein-coupled receptor repertoire of gastric ghrelin cells. Mol Metab 2:376-392
10. Forbes S, Stafford S, Coope G, Heffron H, Real K, Newman R, Davenport R, Barnes M, Grosse J, Cox H (2015) Selective FFA2 agonism appears to act via intestinal PYY to reduce transit and food intake but does not improve glucose tolerance in mouse models. Diabetes 64:3763-3771
11. Grundmann M, Tikhonova IG, Hudson BD, Smith NJ, Mohr K, Ulven T, Milligan G, Kenakin T, Kostenis E (2016) A molecular mechanism for sequential activation of a G protein-coupled receptor. Cell Chem Biol 23:392-403
12. Hoveyda H, Brantis CE, Dutheuil G, Zoute L, Schils D, Bernard J (2010) Compounds, pharmaceutical composition and methods for use in treating metabolic disorders. PCT Int Appl WO2011076732
13. Hoveyda H, Brantis CE, Dutheuil G, Zoute L, Schils D, Bernard J (2011a) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases. PCT Int Appl WO2011076734
14. Hoveyda H, Brantis CE, Dutheuil G, Zoute L, Schils D, Fraser G (2011b) Compounds, pharmaceutical composition and methods for use in treating for use in the treatment of gastrointestinal disorders. PCT Int Appl WO2011076732
15. Hoveyda H, Schils D, Zoute L, Parcq J (2011c) Pyrrolidine or thiazolidine carboxylic acid derivatives, pharmaceutical compositions and methods for use as in treating metabolic disorders as agonists of G-protein coupled receptor 43 (GPR43). PCT Int Appl WO2011073376
16. Hoveyda H, Zoute L, Lenoir F (2011d) Azepanes, azocanes and related compounds as GPR43 modulators and their preparation and use for the treatment of inflammatory, gastrointestinal and metabolic disorders. PCT Int Appl WO2011151436
17. Hudson BD, Christiansen E, Murdoch H, Jenkins L, Hansen AH, Madsen O, Ulven T, Milligan G (2014) Complex pharmacology of novel allosteric free fatty acid 3 receptor ligands. Mol Pharmacol 86:200-210
18. Hudson BD, Due-Hansen ME, Christiansen E, Hansen AM, Mackenzie AE, Murdoch H, Pandey SK, Ward RJ, Marquez R, Tikhonova IG, Ulven T, Milligan G (2013) Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. J Biol Chem 288:17296-17312
19. Hudson BD, Tikhonova IG, Pandey SK, Ulven T, Milligan G (2012) Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3. J Biol Chem 287:41195-41209
20. Kenakin T (2015) The effective application of biased signaling to new drug discovery. Mol Pharmacol 88:1055-1061
21. Kimura I, Inoue D, Maeda T, Hara T, Ichimura A, Miyauchi S, Kobayashi M, Hirasawa A, Tsujimoto G (2011) Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc Natl Acad Sci U S A 108:8030-8035
22. Kimura I, Ozawa K, Inoue D, Imamura T, Kimura K, Maeda T, Terasawa K, Kashihara D, Hirano K, Tani T, Takahashi T, Miyauchi S, Shioi G, Inoue H, Tsujimoto G (2013) The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun 4:1829
23. Lane JR, Sexton PM, Christopoulos A (2013) Bridging the gap: bitopic ligands of G-protein- coupled receptors. Trends Pharmacol Sci 34:59-66
24. Lee SU, In HJ, Kwon MS, Park BO, Jo M, Kim MO, Cho S, Lee S, Lee HJ, Kwak YS, Kim S (2013) beta-Arrestin 2 mediates G protein-coupled receptor 43 signals to nuclear factor- kappaB. Biol Pharm Bull 36:1754-1759
25. Lee T, Schwandner R, Swaminath G, Weiszmann J, Cardozo M, Greenberg J, Jaeckel P, Ge H, Wang Y, Jiao X, Liu J, Kayser F, Tian H, Li Y (2008) Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. Mol Pharmacol 74:1599-1609
26. Leonard JN, Chu ZL, Bruce MA, Boatman PD (2006) GPR41 and modulators thereof for the treatment of insulin-related disorders. PCT Int Appl WO2006052566
27. Le Poul E, Loison C, Struyf S, Springael JY, Lannoy V, Decobecq ME, Brezillon S, Duprie V, Vassart G, Van Damme J, Parmentier M, Detheux M (2003) Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 278:25481-25489
28. Nilsson NE, Kotarsky K, Owman C, Olde B (2003) Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem Biophys Res Commun 303:1047-1052
29. McNelis JC, Lee YS, Mayoral R, van der Kant R, Johnson AM, Wollam J, Olefsky JM (2015) GPR43 potentiates β-cell function in obesity. Diabetes 64:3203-3217
30. Ma L, Wang T, Shi M, Fu P, Pei H, Ye H (2016) Synthesis, activity and docking study of novel phenylthiazole-carboxamido acid derivatives as FFA2 agonists. Chem Biol Drug Des 88:26-37
31. Milligan G, Shimpukade B, Ulven T, Hudson BD (2016) Complex pharmacology of the free fatty acid receptors. Chem Rev (in press)
32. Milligan G, Stoddart LA, Smith NJ (2009) Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. Br J Pharmacol 158:146-153
33. Mohr K, Schmitz J, Schrage R, Tränkle C, Holzgrabe U (2013) Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors. Angew Chem Int Ed Engl 52:508-516
34. Namour F, Galien R, Van Kaem T, Van der Aa A, Vanhoutte F, Beetens J, Van’t Klooster G (2016) Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects. Br J Clin Pharmacol 82:139-148
35. Nohr MK, Pedersen MH, Gille A, Egerod KL, Engelstoft MS, Husted AS, Sichlau RM, Grunddal KV, Poulsen SS, Han S, Jones RM, Offermanns S, Schwartz TW et al (2013) GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes. Endocrinology 154:3552-3564
36. Park BO, Kim SH, Kong GY, da Kim H, Kwon MS, Lee SU, Kim MO, Cho S, Lee S, Lee HJ, Han SB, Kwak YS, Lee SB, Kim S (2016) Selective novel inverse agonists for human GPR43 augment GLP-1 secretion. Eur J Pharmacol 771:1-9
37. Pizzonero M, Dupont S, Babel M, Beaumont S, Bienvenu N, Blanqué R, Cherel L, Christophe T, Crescenzi B, De Lemos E, Delerive P, Deprez P, De Vos S, Djata F, Fletcher S, Kopiejewski S, L’Ebraly C, Lefrançois JM, Lavazais S, Manioc M, Nelles L, Oste L, Polancec D, Quénéhen V, Soulas F, Triballeau N, van der Aar EM, Vandeghinste N, Wakselman E, Brys R, Saniere L (2014) Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic. J Med Chem 57:10044-10057
38. Priyadarshini M, Villa SR, Fuller M, Wicksteed B, Mackay CR, Alquier T, Poitout V, Mancebo H, Mirmira RG, Gilchrist A, Layden BT (2015) An acetate-specific GPCR, FFAR2, regulates insulin secretion. Mol Endocrinol 29:1055-1066
39. Saniere LRM, Pizzonero MR, Triballeau N, Vandeghinste NER, De VSIJ, Brys RCX, Pourbaix-L’ebraly CD (2012) Preparation of azetidine derivatives as GPR43 antagonists useful in the treatment of metabolic and inflammatory diseases. PCT Int Appl WO2012098033
40. Schmidt J, Smith NJ, Christiansen E, Tikhonova IG, Grundmann M, Hudson BD, Ward RJ, Drewke C, Milligan G, Kostenis E, Ulven T (2011) Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. J Biol Chem 286:10628-10640
41. Schrage R, Schmitz AL, Gaffal E, Annala S, Kehraus S, Wenzel D, Bullesbach KM, Bald T, Inoue A, Shinjo Y, Galandrin S, Shridhar N, Hesse M, Grundmann M, Merten N, Charpentier TH, Martz M, Butcher AJ, Slodczyk T, Armando S, Effern M, Namkung Y, Jenkins L, Horn V, Stoßel A, Dargatz H, Tietze D, Imhof D, Galés C, Drewke C, Muller CE, Holzel M, Milligan G, Tobin AB, Gomeza J, Dohlman HG, Sondek J, Harden TK, Bouvier M, Laporte SA, Aoki J, Fleischmann BK, Mohr K, Konig GM, Tuting T, Kostenis E (2015) The experimental power of FR900359 to study Gq-regulated biological processes. Nat Commun 6:10156
42. Sergeev E, Hansen H, Pandey SK, MacKenzie AE, Hudson BD, Ulven T, Milligan G (2016) Non-equivalence of key positively charged residues of the free fatty acid 2 receptor in the recognition and function of agonist versus antagonist ligands. J Biol Chem 291:303-317
43. Smith NJ, Stoddart LA, Devine NM, Jenkins L, Milligan G (2009) The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1. J Biol Chem 284:17527-31759
44. Smith NJ, Ward RJ, Stoddart LA, Hudson BD, Kostenis E, Ulven T, Morris JC, Tränkle C, Tikhonova IG, Adams DR, Milligan G (2011) Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator. Mol Pharmacol 80:163-173
45. Srivastava A, Yano J, Hirozane Y, Kefala G, Gruswitz F, Snell G, Lane W, Ivetac A, Aertgeerts K, Nguyen J, Jennings A, Okada K (2014) High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature 513:124-127
46. Stoddart L, Smith NJ, Milligan G (2008a) International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol Rev 60:405-417
47. Stoddart LA, Smith NJ, Jenkins L, Brown AJ, Milligan G (2008b) Conserved polar residues in transmembrane domains V, VI, and VII of free fatty acid receptor 2 and free fatty acid receptor 3 are required for the binding and function of short chain fatty acids. J Biol Chem 283:32913-32924
48. Sum CS, Tikhonova IG, Neumann S, Engel S, Raaka BM, Costanzi S, Gershengorn MC (2007) Identification of residues important for agonist recognition and activation in GPR40. J Biol Chem 282:29248-29255
49. Swaminath G, Jaeckel P, Guo Q, Cardozo M, Weiszmann J, Lindberg R, Wang Y, Schwandner R, Li Y (2011) Mutational analysis of G-protein coupled receptor--FFA2. Biochem Biophys Res Commun 405:122-127
50. Tang C, Ahmed K, Gille A, Lu S, Grone HJ, Tunaru S, Offermanns S (2015) Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes. Nat Med 21:173-177
51. Ulven T (2012) Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front Endocrinol (Lausanne) 3:111
52. Vinolo MA, Ferguson GJ, Kulkarni S, Damoulakis G, Anderson K, Bohlooly-Y M, Stephens L, Hawkins PT, Curi R (2011) SCFAs induce mouse neutrophil chemotaxis through the GPR43 receptor. PLoS One 6, e21205
53. Wang Y, Jiao X, Kayser F, Liu J, Wang Z, Wanska M, Greenberg J, Weiszmann J, Ge H, Tian H, Wong S, Schwandner R, Lee T, Li Y (2010) The first synthetic agonists of FFA2: discovery and SAR of phenylacetamides as allosteric modulators. Bioorg Med Chem Lett 20:493-498
54. Won YJ, Lu VB, Puhl HL 3rd, Ikeda SR (2013) Beta-hydroxybutyrate modulates N-type calcium channels in rat sympathetic neurons by acting as an agonist for the G-protein-coupled receptor FFA3. J Neurosci 33:19314-19325
55. Zaibi MS, Stocker CJ, O’Dowd J, Davies A, Bellahcene M, Cawthorne MA, Brown AJ, Smith DM, Arch JR (2010) Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids. FEBS Lett 584:2381-2386